Combining chemotherapy with new drugs that target a protein that helps cancer cells to withstand chemotherapy could drastically improve treatment, according to research published in Cancer Cell.
Researchers at the University of Manchester carefully studied a network of proteins that kick into action when cancer cells in the lab are treated with a class of chemotherapy drugs called taxanes*. These drugs are commonly used to treat several cancers - including breast, ovarian and prostate cancers. But not all cancers respond to them, and it's difficult to predict which patients will benefit.
The Cancer Research UK-funded scientists measured the strength of this network in a range of cancers** to try and find out why some are more likely to respond to taxane-based chemotherapy and why some are more likely to be resistant.
The team identified one particular component of this network - a protein called Bcl-xL - which helps the cancer cells survive treatment by blocking the self-destruct process that normally kills cells when treated with chemotherapy drugs.
Drugs to block Bcl-xL are already available and, by combining them with taxanes, the researchers showed in the lab that the combination of treatments killed far more cancer cells than taxanes alone.
Study leader Professor Stephen Taylor, Cancer Research UK Senior Research Fellow and Leech Professor of Pharmacology at the University of Manchester, said: "This important research shows us there's potential to boost the cancer-fighting power of chemotherapy - and do more with less.
"This new combination could 'soften-up' cancer cells, making it easier for chemotherapy to deliver the final blow and destroy the tumour. And the good news is that drugs targeting Bcl-xL are already out there and being tested in clinical trials.
"Using this combination of drugs could improve treatment for patients receiving taxanes and lower their chemotherapy dose, which would also help to reduce side-effects."
Dr Emma Smith, senior science information officer at Cancer Research UK, said: "Predicting which patients will benefit most from chemotherapy is essential if we're going to make cancer treatments more effective and kinder.
"In cases where chemotherapy doesn't seem to work straight away, we could add drugs that target Bcl-xL and hopefully see a real difference. It's still early days for this research but, if the results are confirmed in clinical trials, it has the potential to improve treatment for thousands of cancer patients."
###
For media enquiries please contact Greg Jones on 020 3469 8311 or, out-of-hours, the duty press officer on 07050 264 059
Notes to Editors:
Topham, C., et al, 'MYC is a major determinant of mitotic cell fate'. Cancer Cell, 2015.
*Examples of taxane chemotherapy agents include paclitaxel (Taxol) and docetaxel (Taxotere)
**The researchers studied the effects of taxenes in cell lines derived from colon, lung, breast, cervical and ovarian cancers.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
- Today, 2 in 4 people survive cancer. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.
Journal
Cancer Cell